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Abstract: Regenerative medicine has rapidly evolved, due to progress in cell and molecular biology
allowing the isolation, characterization, expansion, and engineering of cells as therapeutic tools.
Despite past limited success in the clinical translation of several promising preclinical results,
this novel field is now entering a phase of renewed confidence and productivity, marked by the
commercialization of the first cell therapy products. Ongoing issues in the field include the use of
pluripotent vs. somatic and of allogenic vs. autologous stem cells. Moreover, the recognition that
several of the observed beneficial effects of cell therapy are not due to integration of the transplanted
cells, but rather to paracrine signals released by the exogenous cells, is generating new therapeutic
perspectives in the field. Somatic stem cells are outperforming embryonic and induced pluripotent
stem cells in clinical applications, mainly because of their more favorable safety profile. Presently,
both autologous and allogeneic somatic stem cells seem to be equally safe and effective under
several different conditions. Recognition that a number of therapeutic effects of transplanted cells are
mediated by paracrine signals, and that such signals can be found in extracellular vesicles isolated
from culture media, opens novel therapeutic perspectives in the field of regenerative medicine.
Keywords: stem cells; pluripotent stem cells; autologous cell transplantation; allogenic cell
transplantation; cell therapy; paracrine signaling; extracellular vesicles; industry manufacturing
1. Introduction
Regenerative medicine is a young discipline that has rapidly evolved during the last twenty
years due to the remarkable progress of cell and molecular biology, which has paved the way to the
use of living cells (particularly stem cells) as therapeutic tools for a variety of diseases. Expectations
from both patients and physicians have led to an accelerated transfer of these novel therapies from
bench to bedside without sufficient knowledge of the pathophysiological mechanisms involved. Thus,
inconsistent outcomes of the first phase II–III clinical trials of cell therapy have resulted in severe
financial losses and reduced confidence in the possibilities of the field. According to the “Gartner’s
curve”, ground-breaking innovations may result in a peak of inflated expectations, followed by
a trough of disillusionment when they fail to deliver as promised. However, if the innovation is based
on solid foundations, it is possible to learn from previous mistakes and open a new positive phase,
the “plateau of productivity” [1]. Regenerative medicine seems to be now in this phase, marked by the
commercialization of the first cell therapy products following approval by regulatory authorities and
by the entry of big pharma into the field. Possibly, improved patient selection and better knowledge of
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tissue biology (i.e., host tissue interaction with transplanted cells) has helped entrance into this new
phase. However, several unresolved issues are still a matter of debate, including the preferential use of
pluripotent vs. somatic, and of allogenic vs. autologous stem cells. In addition, the prevailing concept
of stem cells as “spare parts” has now been modified by the acknowledgment that, in several instances,
the observed beneficial effects of cell transplantation are not due to integration and differentiation of
transplanted cells into the host tissue, but rather result from complex paracrine signals released by the
exogenous cells themselves.
2. Pluripotent vs. Somatic Stem Cells
Pluripotent stem cells (PSCs) represent the original revolutionary promise of regenerative
medicine, because of their ability to self-renew indefinitely, and because in theory they can also
differentiate into any cell type in the body, thus providing functional replacement or trophic support
to dysfunctional cells and tissues in various diseases. Expectations for their therapeutic application
in regenerative medicine date back almost two decades, when human embryonic stem cells (hESCs)
were first derived from the inner cell mass of embryos [2]. Researchers throughout the world spent
considerable efforts improving expansion and differentiation protocols, in order to obtain large
amounts of the desired cell phenotype free of pluripotent leftovers, thus minimizing the risk of
teratoma formation. Following extensive research in animal models, early clinical applications were
concentrated in the areas of retinal diseases, cardiac ischemia, diabetes mellitus, and spinal cord
injuries [3]. Retinal diseases are a preferential area of application since the eye is believed to be
an immune privileged site, and being an isolated organ, it allows local administration of the cells with
minimal systemic distribution. In a recent report, a significant vision improvement was demonstrated
in the majority of 18 patients with Age-related Macular Degeneration (AMD) or with Stargardt’s
Macular Dystrophy, a disease resulting in retinal cell degeneration and central vision loss in children
after the age of ten [4]. Transplanted patients were followed up for a median of 22 months by serial
systemic, ophthalmic, and imaging examinations. There was no evidence of adverse proliferation,
rejection, or serious ocular or systemic reactions, and adverse events were associated with vitreoretinal
surgery and immunosuppression. Thirteen out of 18 patients (72%) had patches of increasing subretinal
pigmentation, consistent with transplanted retinal pigment epithelium. Best-corrected visual acuity,
monitored as part of the safety protocol, improved in ten eyes, improved or remained the same in
seven eyes, and decreased by more than ten letters in one eye, whereas the untreated fellow eyes did
not show similar improvements in visual acuity. Vision-related quality-of-life measures increased
after transplantation for general and peripheral vision, as well as near and distance activities, both in
patients with AMD and in patients with Stargardt’s macular dystrophy.
The technology of induced pluripotent stem cells (iPSCs) developed by Yamanaka [5] involves the
reprogramming of differentiated somatic cells into a pluripotent state by the introduction of a cocktail
of factors to “reset” the transcriptional program of the cell back to an embryonic state. The aims were
the generation of autologous, and thus non-immunogenic, patient-specific cell lines for transplantation,
as well as to avoid ethical concerns related to the use of human embryos. Following encouraging
results in non-human primates, the first in-man clinical iPSC-based trial was announced in 2014, aimed
at treating patients affected by the exudative form of AMD with autologous iPSC-derived retinal
pigment epithelium (RPE) sheets [3]. In the first treated patient, the RPE sheet transplanted under
the macula survived well without any findings of immune rejection nor of excessive proliferation,
and no significant adverse event was observed during a one-year follow-up. Retinal imaging showed
improvement of the exudative alterations, best corrected visual acuity was maintained without
additional anti-VEGF therapy, and the score of the Visual Function Questionnaire improved. A second
patient was then enrolled, but her iPSCs reportedly contained a mutation, potentially in an oncogene.
Thus, the trial was put on hold pending a possible redesign [6].
A major obstacle in the development of iPSC-based therapies is the level of artificial manipulation.
ESCs first need to be artificially maintained and propagated in an undifferentiated status, and are
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then directed towards a specific differentiation pathway. For the generation of iPSCs, somatic
cells are reprogrammed to a pluripotent state, and then differentiated as above. The whole
process thus generates a series of risk factors (for a review, see e.g., [7,8]).The risk of teratoma
formation is related to the contamination of human iPSC-derived differentiated cells with residual
undifferentiated and pluripotent cells. Chromosomal aberrations can already be present in the somatic
cells before reprogramming (especially when derived from aged individuals), or may result from the
reprogramming process, or from culture conditions [9]. Indeed, it has been reported that the karyotype
of human iPSCs can become unstable during prolonged culture in vitro, exhibiting resistance to
apoptosis, altered differentiation patterns, and persistent stem cells populations in teratomas [10].
Moreover, several oncogenes were found to be overexpressed in iPSCs [11,12]. Further research
led to the development of alternative, virus-free derivatization methods, limiting the tumorigenic
risk associated with the genomic integration of reprogramming factors. These non-integrating
reprogramming protocols, in particular mRNA-based techniques, guaranteed higher efficiency,
improved reliability in terms of success rate and low frequency of possible de novo genetic aberrations,
giving rise to iPSCs displaying epigenetic patterns close to those of ESCs lines and able to differentiate
into the three germ layers [13]. Recently, Luni and colleagues described a method that combined the
use of non-integrating modified mRNAs with a microfluidic chip, enabling automated and highly
efficient reprogramming of human somatic cells to iPSCs, to date with the highest efficiency reported in
literature. These so-called µ-hiPSC are highly homogeneous, with 85% of cells expressing pluripotency
markers, are karyotypically normal after expansion for 12 passages, and can also be differentiated
on-chip into different cell types [14]. Improved clinical safety could possibly be reached by purifying
iPSCs-derived differentiated cells using fluorescence-activated cell sorting (FACS) with antibodies
against pluripotency markers [15] or by other techniques such as chemical ablation by targeting
tumorigenicity-associated proteins or by discriminating undifferentiated iPSCs for their different
electrochemical potential [16]. Moreover, next-generation sequencing techniques could be applied in
order to establish routine tests for the genetic integrity of iPSCs produced for therapeutic application [7].
Still, these cell products are subjected to a high level of scrutiny. As stated above, clinical trials
involving local cell administration in a contained environment are preferred due to limited availability
of data on toxicity and biodistribution, as well as because of concerns regarding contamination with
residual pluripotent cells, tumorigenic risks, and ectopic tissue formation.
Somatic stem cells (SSCs) are considered safer therapeutic tools, since in theory they can be
administered without further manipulation following isolation from tissues. In practice, with the
exception of hematopoietic stem cells (HSCs), in vitro expansion is required in order to obtain
sufficient amounts for therapeutic applications, a process that might result in genetic abnormalities.
Not unexpectedly, in vitro expansion yields reproducible results with high turnover tissues such as
epithelia, paving the way for the successful cell therapy of cutaneous and corneal lesions [17,18].
However, mesenchymal stem/stromal cells (MSCs) now seem to represent the most promising tool
in Regenerative Medicine, even surpassing HSCs in the scientific literature (4435 publications on
MSCs vs. 3797 publications on HSCs in the year 2015). Current experimental therapeutic applications
mainly exploit the immune modulatory properties of MSCs [19], as well as their ability to protect
organs and tissues from a variety of injuries favoring regeneration with restitutio ad integrum [20].
Currently, 271 open, recruiting interventional studies using MSCs (conditions: NOT tumor, cancer,
proliferative disorders) are registered at the National Institute of Health website (clinicaltrials.gov).
Target immune disorders include graft-versus-host disease (GVHD), diabetes, inflammatory bowel
disease, multiple sclerosis, amyotrophic lateral sclerosis, Sjögren syndrome, rheumatoid arthritis,
systemic sclerosis and systemic lupus erythematosus. These figures clearly indicate an enduring
confidence in the therapeutic possibilities offered by MSCs, even in the face of limited clinical evidence.
Importantly, a recent meta-analysis supported the safety of MSC-based treatments after evaluating 36
studies, eight of which were randomized controlled trials [21]. Target diseases included ischemic stroke,
Crohn’s disease, cardiomyopathy, myocardial infarction, GVHD and healthy volunteers, with a total
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of 1012 participants. No association was found between MSCs and acute infusion-related toxicity,
organ system complications, infection, death or malignancy. The only significant association was
between MSC infusion and transient fever. However, larger scale controlled clinical trials with rigorous
reporting of adverse events are required to further define the safety profile of MSCs. Most clinical
studies are uncontrolled phase I/II trials enrolling a limited number of patients, sometimes under
poorly defined conditions, and reports of failures have been frequent [22,23]. Some positive results are,
however, being produced in larger phase III or in better conducted phase II studies.
A phase III double-blind, placebo-controlled clinical trial using commercial allogeneic MSCs
(Prochymal®, Osiris Therapeutics Inc., Columbia, MD, USA) for the treatment of GVHD included
two different protocols [24]. The first protocol evaluated the safety and efficacy of Prochymal in
association with steroid therapy in 192 patients. No significant beneficial effect on 90-day survival
was observed in this patient population. The second protocol evaluated the safety and efficacy of
Prochymal in patients resistant to corticosteroid therapy. The primary endpoint was a sustained
complete response for at least 28 days. This endpoint was only met in the subgroups of patients with
steroid-refractory hepatic and gastrointestinal GVHD. Importantly, Prochymal showed a stronger trend
of improvement in response rates in pediatric patients (86% vs. 57%, p = 0.094, n = 28). No adverse
events were registered. Despite the mixed results of the trial, on May 2012, the sponsor company
received market authorization from Canada Health Authorities for the treatment of steroid-resistant
GVHD in pediatric patients, making Prochymal the world’s first approved drug having stem cells
as its active ingredient. Additional evidence of efficacy of the drug in this pediatric population was
provided in further studies [25].
A multicenter randomized, double-blind trial recruited 212 Crohn’s disease patients with complex
perianal fistulas with inadequate response to previous therapies, including anti-tumor necrosis factors
(TNFs). Patients were randomized to receive either placebos, or a single intralesional injection of
120 million allogeneic, expanded, adipose-derived stem cells (Cx601) [26]. The primary endpoint of
the study was combined remission at 24 weeks, and it was analyzed again at 52 weeks as a secondary
variable. A significantly greater proportion of patients treated with Cx601 versus placebo, achieved
combined remission in the intention-to-treat (ITT) population (53 of 107 (50%) vs. 36 of 105 (34%);
difference 15.2%, 97.5% CI 0.2–30.3; p = 0.024) and modified ITT populations (53 of 103 (51%) vs. 36 of
101 (36%); 15.8%, 0.5–31.2; p = 0.021). 18 (17%) of 103 patients in the Cx601 group versus 30 (29%) of
103 in the placebo group experienced treatment-related adverse events, the most common of which
were anal abscess (six in the Cx601 group vs. nine in the placebo group) and proctalgia (five vs. nine).
Of note, 75% of responders exhibited persistence in remission from week 24 to week 52. Importantly,
these patients did not stop their maintenance therapy, and indeed it was shown that drugs usually
administered in Crohn’s disease do not affect MSC function [27].
Results of a clinical study on intravenous (iv) MSC administration as a therapeutic approach for
chronic heart failure have been presented at the European Society of Cardiology Congress 2016 [28].
This phase IIa single-blind, placebo-controlled crossover clinical trial evaluated iv infusion of allogeneic
ischemia-tolerant mesenchymal stem cells (itMSCs) in 22 patients with non-ischemic cardiomyopathy
and a left ventricular ejection fraction of less than 40%. Patients were evaluated at baseline, at 90 days
and at 180 days. No differences were found in the incidence of adverse events between the placebo and
the itMSC-treated group. iv itMSC administration significantly improved several endpoints related to
clinical efficacy, including the six-minute walk test (p = 0.02) and the Kansas City Cardiomyopathy
Questionnaire (KCCQ) Clinical Summary score (p = 0.02). This study also suggests that intravenously
administered itMSCs suppress inflammation, a critical pathogenic element in the progression of heart
failure, as there was a statistically significant reduction in natural killer (NK) cells, which correlated
with the improvement in left ventricular ejection fraction.
In another recent report [29], 18 patients with stable, chronic stroke were enrolled in a two-year,
open-label, single-arm study to evaluate the safety and clinical outcomes of surgical intra-cranial
transplantation of modified bone marrow-derived MSCs (SB623). Six patients experienced six serious
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adverse events associated with the transplantation procedure, but all recovered without sequelae.
The sixteen patients who completed the 12 month-follow-up showed significant improvement for
the European Stroke Scale, the National Institutes of Health Stroke Scale and the Fugl-Meyer motor
function total score, while no changes were observed in the modified Rankin Scale. The area of
magnetic resonance T2 fluid-attenuated inversion recovery signal change in the ipsilateral cortex
1 week after implantation significantly correlated with clinical improvement at 12 months. Thus, in this
interim report, intracranial transplantation of MSCs was safe and associated with clinical improvement.
In summary, at present SSCs seem to be far ahead of PSCs in clinical applications. Clearly,
the safety profile of PSCs still needs to be improved to allow their further development as
therapeutic tools.
3. Allogenic vs. Autologous Cells
The use of allogeneic versus autologous cells represents an unsettled issue in SSC clinical
applications. Studies in vitro and in vivo with MSCs showed similar efficacy of the two cell sources in
suppressing immune response and stimulating tissue regeneration [30–33], and no serious adverse
events were reported in clinical trials with allogeneic MSCs. Allogenic transplants generally need
constant immunosuppression to prevent rejection of grafted cells. However, the above-cited clinical
trials reporting successful results with MSCs for the treatment of pediatric GVHS, fistulae in Crohn’s
disease and chronic heart failure were all using allogenic cells. MSCs have been considered immune
privileged cells because express very low levels of MHC class I, no MHC class II and do not induce
activation of allogeneic lymphocytes [34], However, allogenic MSCs are prone to cytotoxic lysis under
inflammatory conditions in vitro, and induce the production of complement-activating antibodies
in vivo [35]. Moreover, stimulated NK cells can lyse both autologous and allogeneic MSCs [36]. In vivo
studies showed that MSC survival following transplantation is limited [37,38]. Therefore, persistent
engraftment of transplanted cells does not seem to be a prerequisite for their therapeutic efficacy,
suggesting that the observed clinical benefits result from a time-limited effect.
While the use of autologous MSCs may seem more desirable, none of the published trials in
GVHD have employed autologous cells, because of the risk of transmitting tumor cells from the
hematologic malignancy under treatment back to the recipient and of concerns about possible genetic
abnormalities resulting from prior cytotoxic chemotherapy. Autologous MSCs have been used in other
clinical applications, but in some pathologic conditions cells may harbor abnormalities associated
with the disease being treated [39]. Obtaining a number of cells sufficient for clinical use may require
6–8 weeks of culture, a timeframe that may not be compatible with the clinical needs of individual
patients, and autologous cells are not always suitable for efficient ex vivo expansion. On the other
hand, allogenic cells are available “off the shelf,” also allowing better standardization and reducing
costs of production. This would increase the number of patients that could benefit from such therapies.
There is however, a need for reliable specific in vitro potency assays to predict the clinical efficacy of
different cell preparations.
The development of broadly human leukocyte antigen (HLA)-compatible cell lines was theorized
a decade ago [40]. Such cell lines could be generated either by ESCs [41] or by iPSCs [42] to meet most
of the needs for HLA-I compatible cell and tissue transplants in the population. The feasibility and
actual clinical applicability of such “super donors” needs further investigation.
4. Replacement vs. Regeneration
According to one early definition, Regenerative Medicine involves “the engineering and growth
of functional biological substitutes in vitro and/or the stimulus to regeneration and remodeling of
tissues in vivo for the purpose of repairing, replacing, maintaining or enhancing tissue and organ
functions.” [43]. The early years of this novel discipline were dominated by the theory of “replacement”,
and indeed, as reported above, this concept seems to work well with epithelial tissues such as the skin
and the cornea. However, the results were less clear with more complex, slow-turnover tissues such as
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those in heart, the brain, or the liver. In animal studies, the disproportion between significant functional
recovery and poor cell engraftment and persistence suggested an indirect primary mechanism other
than the structural integration of transplanted cells into injured tissues. This was particularly evident in
studies on experimental cell transplantation as a therapy for myocardial infarction [44]. The secretion of
cytoprotective factors by MSCs was first reported by Gnecchi and colleagues [45]. In their experimental
model, the finding that transplantation of genetically modified MSCs could prevent ventricular
remodeling and reestablish heart function in less than 72 h following surgical myocardial infarction
raised the possibility of an action other than a myogenic differentiation that would not take place in such
a short time period. Indeed, similar improvements were shown in the same model, following injection
of MSC-conditioned medium, pointing to paracrine signaling as the primary mechanism underlying the
beneficial effect of cell therapy. It is now well established that stem cells transplanted into injured body
sites secrete a variety of factors inhibiting apoptosis, enhancing angiogenesis, stimulating endogenous
stem cells and inhibiting fibrosis, thus promoting tissue restitutio ad integrum [46,47]. The underlying
molecular mechanisms are also being unraveled [48]. Regarding MSC-mediated immunomodulation,
several soluble factors have been proposed to mediate the effect, including transforming growth
factor-β1 (TGF-β1), prostaglandin E2 (PGE2), hepatocyte growth factor (HGF), indoleamine-pyrrole
2,3-dioxygenase (IDO), nitric oxide (NO) and interleukin-10 (IL-10). Although several secreted factors
are involved in the immunomodulation of MSCs, their relative relationship remains unclear. The effect
of soluble factors on the activity of MSCs may vary depending on the tissue of origin of the cells, on
target cell phenotype and on the microenvironment. Indeed, the detailed mechanisms underlying the
immune modulatory effects of MSCs are not yet sufficiently understood [49]. Though it is indisputable
that MSC therapy contributes to immunosuppression, further elucidation of the detailed biological
mechanisms involved in this process is required. It should also be noted that some cytokines or
chemokines released from MSCs can act as promoters of inflammation. Understanding the delicate
balance between beneficial and potentially harmful secreted factors is a key issue to successfully exploit
the immune modulatory effects of MSCs [50].
5. Novel Technologies for Bioprocessing of Advanced Cellular Therapies
5.1. Automated vs. Non-Automated Procedures for Cell Culture
Once manipulated outside the body, cells constitute a drug—more specifically, an advanced
therapy medicinal product (ATMP)—whose production is regulated by competent national and
international authorities. Cell therapy products described in the previous chapters require various
manufacturing methods [51]. The choice of the right cell culture system depends on various factors i.e.,
type of cells, scale of production, intended use, safety level of the laboratory, and the drug development
strategy [52,53]. Proper selection of the production process strategy is the key factor in the commercial
success of the drug product (Table 1).
Table 1. Production process parameters characteristic for different advanced therapy medicinal
products (ATMPs).
ATMP BatchVolume
Primary
Culture Upstream Downstream
Cost per
Cell Batch
Tissue engineering ++ Manual NA NA ++++
Autologous MSCs ++ Manual NA NA +++
Allogeneic MSCs +++ Manual Automated Semi-automated ++
MSC-EVs ++++ Manual Automated Automated +
MSCs: Mesenchymal stem cells; EVs: Extracellular vesicles (see text); Upstream process: Cell expansion and product
harvesting from low volume starting material up to a large volume culture of the intermediate product; Downstream
process: Intermediate product concentration, purification and packaging from large volume bioproduction system
up to low volume final product vials. NA: not applicable; +: Very low; ++: Low; +++: Medium; ++++: High.
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In general, autologous cells require low-volume batch manufacturing processes, while allogenic
cell production maximizes a single batch volume. Cell therapy products can be produced in automated,
large volume and/or high-throughput bioreactor systems, but also by manual procedures performed by
skilled personnel. The cell therapy product’s characteristics and its intended usage usually determine
aspects of the production process. For example, the most rational choice for allogenic cell products
targeting a high prevalence disease would be a large volume bioreactor system. On the other hand,
bio-printed implants for tissue reconstruction would require an individual protocol, and customized
non-automated production. Batch definition is a critical factor for planning the cell manufacturing
process, and it is quite different for allogenic and autologous products. One batch of an autologous cell
therapy product usually provides a single dose for one patient, while one batch of an allogenic product
can provide hundreds or thousands of doses for multiple patients. Cell expansion of a personalized cell
therapy product can be performed manually in a classical one-layer or multiple-layer two dimensions
(2D) culture vessel, yielding up to hundreds of millions of cells. Some autologous products require
a high-throughput production e.g., chimeric antigen receptor-T cells. In such cases, multiple bioreactors
can work in parallel, providing a high number of low-volume batches of individual products. In the
latter case, the system can be fully automatized in a similar way to large-volume bioreactor systems.
Currently available large volume production systems are delivering the most cost-efficient products,
due to the economy of scale, and significant reduction of space and personnel required for the
production of a single dose. The key advantages of the automated systems are (i) reduction of
operator-related errors and batch-to-batch variabilities; (ii) cross-contamination risk reduction in
a low-grade biosafety environment; (iii) higher efficiency and traceability due to continuous monitoring
and control of the cell culture parameters; (iv) time and personnel reduction; (v) the possibility of
using a lower grade environment for the production process.
5.2. Defined vs. Non-Defined Culture Media
The quality of the reagents used for manufacturing of the cell therapy products has a critical
influence on the purity and safety of the drug. For MSC production, standard protocols used for cell
expansion require the use of bovine serum, usually not exceeding 15% of a total volume, since this
ensures good adhesion of MSCs to most of the plastic surfaces and good cell growth. On the other hand,
animal serum carries an infection risk. In addition, the bovine serum properties can vary between
the batches, affecting both the reproducibility and quality of the product. Moreover, increasing
demand could result in shortages of the product. In some cases, human platelet lysate can be used as
a substitute for the bovine serum. However, platelet lysate has also an undefined composition, with
large batch-to-batch variability and carries an infection risk. Defined media containing recombinant
growth factors, selected proteins and amino acids, can improve the safety and reproducibility of
ATMP production, but still suffer from drawbacks, such as impaired plastic adherence of MSCs [54].
Better understanding of the factors controlling cell adhesion will allow the development of more
efficient production systems in the future.
6. From Cells to Cell Products: Introducing Extracellular Vesicles
As stated above, it is now fully appreciated that transplanted stem cells exert many of their
pro-regenerative and immune modulatory effects via paracrine signaling. The traditional view of
cell–cell communication consists in the release of bioactive molecules, resulting in a complex mixture
whose local precise composition is largely undetermined. However, it has been known for many years
that cells also secrete membrane vesicles, now named “extracellular vesicles (EVs)”, composed of
a lipid bilayer including transmembrane proteins and enclosing cytoplasmic components [55–58].
EVs are best classified according to their intracellular origin, although the heterogeneity of these
nanoparticles is very complex and only partially understood. Apoptotic bodies are released through
outward blebbing and fragmentation of the cell membrane during the process of apoptosis, and exhibit
a wide size range of 50–2000 nm. Shedding vesicles (also named microvesicles), ranging from 50 to
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1000 nm in diameter, are released by direct outward budding of the plasma membrane through the
disruption of cortical cytoskeleton. Exosomes are apparently less heterogeneous in volume, ranging in
size from 30 to 120 nm, are derived from multivesicular bodies (MVBs), a late endosomal compartment,
and are secreted via fusion of MVBs with the plasma membrane. Such tiny vesicles are complex
biological machines that can convey signals by interacting at the cell surface, by internalization into
endocytic compartments or by fusion with plasma membranes. EV complexity can be inferred by their
composition, including proteins, nucleic acids and lipids, differing to variable extents depending on
the tissue of origin, and on a variety of stimuli applied to the parent cells. More than 4000 different
proteins and 2400 different RNAs are described in the exosome database ExoCarta, all of them
potentially involved in the transmission of specific signals. In parallel with the recognition of
their biological importance, EVs have become an object of increasing interest for possible clinical
applications, and many authorities now believe they will replace their cells of origin as therapeutic
tools, because of several reasons. Regarding safety, tumorigenic risk and ectopic colonization appear
to be less of a concern with EVs than with living cells. Results in animal models suggest that local EV
administration is feasible, e.g., for lung diseases (inhalant or intratracheal), to reach the central nervous
system via the intranasal route, or as topical treatments of ocular diseases. Since EVs are not living
cells reacting to different environments, but rather convey a definite set of signals, their effects should
be both more predictable and reproducible. The regenerative and immunomodulatory effects of MSCs
seem to be largely mediated by EVs (Table 2), and a case of successful treatment with MSC-EVs in
a patient with steroid-resistant GVHD has been reported [59].
Table 2. Preclinical in vivo studies on the immune modulatory and regenerative effects of
MSC-extracellular vesicles (EVs).
Source of EVs Methodology Results Reference
Rat BM-derived MSCs Rat Acute Kidney Injury (AKI)induced by gentamicin (G). Improved renal histology and function. [60]
Human embryonic stem
cell-derived MSCs Myocardial infarction in mice. Reduced infarct area. [61]
Human BM-derived MSCs AKI induced by ischemia-reperfusion injury in rats. Improved renal histology and function. [62]
Human BM-derived MSCs
In vitro: EVs on cisplatin-
induced apoptosis of human
renal tubular epithelial cells.
In vitro: EVs up-regulated in
cisplatin-treated human tubular
epithelial cells anti-apoptotic genes,
and down-regulated genes leading to
cell apoptosis.
[63]
In vivo: Cisplatin-induced AKI. In vivo: Improved renal function andhistology, improved survival.
Human UC-derived MSCs
cultured under hypoxia Rat hindlimb ischemia model. Improved blood flow recovery. [64]
Murine BM-derived MSCs Hypoxia-induced pulmonaryhypertension in rats.
Inhibition of vascular remodeling and
of hypoxic pulmonary hypertension. [65]
Human umbilical cord
mesenchymal stem cells
In vitro: treatment with cisplatin
alone in NRK-52E cells.
In vitro: Reversal of cisplatin induced
apoptosis and oxidative. [66]
In vivo: cisplatin-induced Acute
Kidnay Injury (AKI) rat models.
At 24 h after treatment with
cisplatin, EVs injected into
the kidneys.
In vivo: Improved kidney histology
and biochemical parameters of
kidney function.
Human BM-derived MSCs
cultured under hypoxia
Acute myocardial infarction rat
model.
Improved blood flow recovery, reduced
infarct size and preserved cardiac
systolic and diastolic performance.
[67]
Int. J. Mol. Sci. 2017, 18, 1021 9 of 17
Table 2. Cont.
Source of EVs Methodology Results Reference
Human UC-derived MSCs Rat model of skin deepsecond-degree burn wound.
EV-treated wounds exhibited
accelerated re-epithelialization, with
increased expression of CK19, PCNA,
collagen I (compared to collagen III).
Activation of Wnt/β-catenin by
hucMSC-; Wnt4 was found in MSC-EVs,
and promoted β-catenin nuclear
translocation and activity to enhance
proliferation and migration of skin cells.
[68]
Human BM-derived MSCs DSS-induced colitis in mice.
Improved body weight and clinical
score, reduced colon shortening,
reduced TNFα, IL-1β and COX-2
expression in colon mucosa.
[69]
Rat BM-derived MSCs TNBS-induced colitis in rats.
Improved body weight and clinical
score, reduced colon shortening,
improved histology, reduced TNFα,
IL-1β, COX-2 and increased IL-10 in
colon mucosa.
[70]
Human BM-derived MSCs Hypoxic-ischemic injury of thepreterm brain in lamb fetuses.
Improved brain function by reducing
the total number and duration of
seizures, and by preserving
baroreceptor reflex sensitivity,
tendency to prevent hypomyelination.
[71]
BM = Bone Marrow; UC = Umbilical Cord; DSS = Dextran sulfate sodium; TNBS = 2,4,6-trinitrobenzenesulfonic acid.
Administration of allogenic vs. autologous MSC-derived EVs should not be an issue, since
these nanoparticles do not express MHC class I-II [72]. MSC-derived EVs can thus be produced by
“waste” human tissue, such as Wharton jelly from the umbilical cord, and can be readily administered
“off-the-shelf”. Specific cell targeting by EVs can increase the therapeutic index of EV-carried drugs,
both by increasing drug concentration in the affected tissue and reducing unwanted distribution
to other sensitive tissues and organs [73,74]. Clinical-grade EVs have been produced and tested in
preliminary clinical trials on cancer immune therapy [75,76] (Table 3), and no safety concerns emerged
both from past and ongoing EV-based clinical trials [77].
Table 3. Published clinical trials on EV-based therapies-modified from Ohno et al. [77].
Disease (No. of Patients) EV Source Outcome Side Effects Reference
Metastatic melanoma (15) DCs autologous
MART1–HLA-A2 T-cell response
and tumor shrinkage (1); minor
response (1); mixed response (1);
stabilization (2)
No major toxicity;
minor inflammation,
Grade 1 fever (5)
[78]
Non-small cell lung
cancer (9) DCs autologous
MAGE-specific T cell responses
(3); NK cell lysis (2)
No major toxicity; moderate
pain (1), swelling at injection
site (8); mild fever (1)
[76]
Colorectal cancer (37) Ascitic Fluidautologous
EVs + GM-CSF: cytotoxic T cell
resp. to CAP-1 (76.9%);
stabilization (1);
minor response (1)
No major toxicity; moderate
pain, swelling, pruritus at
injection site (37); fever (1),
fatigue (3) and nausea (1)
[79]
GVHD (1) MSCs allogenic
GVHD symptoms improved;
stabilization for several months.
Patient died of pneumonia 7
months post exosome application
No major side-effects [59]
Non-small cell lung
cancer (41) DCs autologous N.D. N.D. [80]
DCs: dendritic cells; N.D.: No data; GM-CSF: granulocyte-macrophage colony-stimulating factor; GVHD:
Graft-versus host disease; IFN-γ: interferon γ.
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Of note, EVs with therapeutic potential are being isolated both from ESC [81] and iPS-derived
cell lines [82–84], suggesting that these nanoparticles might replace their cells of origin in some
clinical applications, thus bypassing both ethical and safety concerns. EVs are also much easier to
produce and cryopreserve under GMP requirements than living cells, with significant cost reductions,
thus eliminating a major barrier to the diffusion of advanced therapies. Manufacturing of the MSC-EVs
represents a good example, implying new standards in drug production and resulting in significant
cost reductions without compromising product quality (Figure 1).Int. J. Mol. Sci. 2017, 18, 1021  11 of 17 
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Figure 1. Bioproduction process of extracell lar vesicles ( s) from mesenchymal stem cells (MSCs).
The entire production process, including final concentration and vial filling, can be performed in
a fully automated and closed system. The quality control of the EVs bioproduction process starts from
analysis of donor eligibility and includes all subsequent production steps (Table 4, Figure 1).
The EVs (final product) are analyzed for size and quantity using state-of-the-art technology, such
as nanoparticle tracking analysis and resistive pulse sensing analysis [85]. In addition, EV phenotyping
must be performed to estimate EV homogeneity and quantity. Each EV batch is analyzed for several
CD markers, including HLA class I/II (negative) and tetraspanin CD63, CD81, CD9 (positive).
The above-mentioned tests should also be complemented by activity assays dedicated for the
intended use of the EV drug e.g., in vitro co-culture with human immune cells to confirm the
immunosuppressive effect of the EV batch. U fortunately, such tests are difficult to stand rdize,
and no reference assay has yet been established. A similar issue has been raised with MSC-based
therapies [86,87]. EVs are hus opening a novel persp ctive in regenerative medicine, promising
to speed up bench-to-bedside development with respect to living cells, as a result of their lower
complexity, easier standardiz tion and reduced production costs. However, it should be stressed that
research on the use of EVs as therapeutic tool is still in its infancy, and that the biological properties
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of these nanoparticles are still poorly understood. For instance, little information is available on
the variability of their complex cargo composition, and on the possibility of pre-determining such
composition by the culture conditions of their cells of origin. The intracellular fate of EVs following
their delivery into target cells is also largely unknown, but preliminary evidence suggests that it can
vary depending on EV phenotype, resulting in profoundly different effects [88]. Most of all, their
feasibility as therapeutic tools has been demonstrated only in animal models, while clinical experience
is limited to the few above cited clinical trials in the field of adoptive immune therapy. Clearly, while
EVs could eventually be used in place of their cells of origin in a series of pro-regenerative and immune
modulatory therapeutic applications, whole cell transplantation will still be necessary to replace
extensive or total loss of functional tissue, such as in the later stages of macular degeneration discussed
above (Figure 2).
In conclusion, a series of successful clinical trials has propelled new confidence in the field
of regenerative medicine, and new products are now being developed on firmer foundations,
learning from past errors and taking advantage of recent technological advances. Presently, EVs
are attracting much interest since they represent a potentially revolutionary therapeutic tool. However,
much has still to be learned regarding their mechanisms of action, as well as regarding their efficacy
and possible side effects in clinical practice.
Table 4. Quality controls for bioprocessing of mesenchymal stem cell-derived extracellular vesicles.
QC Number Tests
Starting material
QC1
• Documents check (including donor’s written consent)
Donor’s medical history check
Donor’s blood sample collection for microbiology and virus tests—results available within
two weeks
Transport time and transport environment monitoring
Transport box and tissue container integrity check
QC2
• Tissue visual inspection
• Fresh tissue viability and integrity test
• Transport medium microbiology test—results available within two weeks
Master bank
QC3
• Cell viability during primary growth continues monitoring of cell culture parameters:
(pH, glucose, temp, humidity, CO2)
Continues monitoring of cell viability and growth rate
Continues monitoring of cell culture parameters: (pH, glucose, temp, humidity, CO2)
Heterogeneity test: MSCs immunophenotyping (fluorescence-activated cell sorting (FACS))
QC4 • Microbiology, endotoxins and mycoplasma tests—results available within two weeks
Working bank
QC5 • Cell recovery after thawing
QC6
• Continues monitoring of cell viability and growth rate during EVs production
Continues monitoring of cell culture parameters: (pH, glucose, temp, humidity, CO2)
EV sizing and quantification (e.g., nanoparticle tracking analysis (NTA), tunable resistive pulse
sensing (TRPS)) from every harvest, final pool and the final product
EV activity test (e.g., T/B cell co-culture assay)
QC7
• Final product test: microbiology and endotoxins—available within two weeks
EV recovery and stability test after cryopreservation and storage at different temperature
(sizing, phenotyping, activity)
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Figure 2. Stem cells vs. extracellular vesicles (EVs) as therapeutic tools. EVs seem to reproduce many
of the regenerative and immunomodulatory effects of their cells of origin, but cells are still required to
replace total loss of tissues.
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